Northland Capital Vadim Alexandre on ImmuPhrama Plc Phase III trial update

Northland Capital Partners Head of research Vadim Alexandre talks to DirectorsTalk about the phase III trial update announced by Immupharma Plc (LON:IMM). Vadim talks us through the highlights and the keys points to take away from this update.